Replies to post #15458 on CytoSorbents Corporation (CTSO)

[clints]

I call bull on the, "Companies are catching up. I'm reading it everywhere". Chan did discuss a couple of products that have been around a few years, but not much of a threat. I obviously can't predict the s/p , although I think we get some upgrades. Chan said we will have increased sales in Q1 2019 from Q4 2018.
On the conf. call today it was mentioned that direct sales have already started in every country listed here, but Poland and that starts in Q2. Seeing positive results from those direct sales currently.
MONMOUTH JUNCTION, N.J., March 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has expanded direct sales of CytoSorb for all applications to Poland and the Netherlands, and for critical care applications in Sweden, Denmark, and Norway. As part of this effort, the company established CytoSorbents Poland Sp. z.o.o., a wholly-owned subsidiary of CytoSorbents Europe GmbH

[hemopure36]

So let me get this straight. The company reported results yesterday that were slightly better than what had been pre-announced in January and somehow this is a negative? Other than the slight delay with Hemodefend, which was out of their control, why should this make the share price drop by 60% from here? Please explain how the earnings release disappointed you, given that it was already announced in January? I think the new push for direct sales is a great move, which will accelerate our presence in hospitals around the world while we await U.S. approval. I was happy with the report yesterday, but I guess naysayers will be naysayers.

[Good Sport]

Harbor6460 - Sounds like your trying to acquire more ctso shares at a lower price bubba !